FDA Approves New Kyprolis & #174; (carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma

The Committee for Medicinal Products for Human Use (CHMP) —a division of the European Medicines Agency—recommended a change to the terms of the marketing authorization for Kyprolis & #174; (carfilzomib) for the treatment of relapsed multiple myeloma. As of July 3, 2016, CHMP approved Kyprolis in combination with dexamethasone alone to treat adult patients who have received at least one prior therapy.
Source: International Myeloma Foundation - Category: Hematology Source Type: news